Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

18.98
Delayed Data
As of Feb 24
 -0.07 / -0.37%
Today’s Change
15.15
Today|||52-Week Range
39.74
+13.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.3B

Company Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the following segments: Research, Molecular Diagnostics, and Companion Diagnostics. The Research segment is focused on the discovery of genes related to major common diseases, and includes corporate services such as finance, human resources, legal, and information technology. The Molecular Diagnostics segment provides testing that is designed to assess the risk for developing disease later in life of the patient, identify the likelihood of responding to drug therapy and guide the dosing to ensure optimal treatment, or assess a the disease progression and disease recurrence of the patient. The Companion Diagnostics segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:
(801) 584-1143

Employees

Shareholders

Other institutional76.41%
Mutual fund holders44.99%
Individual stakeholders3.69%

Top Executives

Mark C. CaponePresident, Chief Executive Officer & Director
Gary A. KingExecutive Vice President-International Operations
R. Bryan RiggsbeeChief Financial Officer, Treasurer & Executive VP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer